Publications by authors named "Alfred Callahan"

Claim this Profile
R
Reply: Hemorrhagic Stroke, All-Cause Death, and Intensive LDL-C Lowering: Evidence From SPARCL and Beyond.
Michael Szarek, Pierre Amarenco, Alfred Callahan, Larry B Goldstein, Henrik Sillesen

J Am Coll Cardiol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories: The SPARCL Trial.
Michael Szarek, Pierre Amarenco, Alfred Callahan, David DeMicco, Rana Fayyad

J Am Coll Cardiol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial.
Pierre Amarenco, Alfred Callahan, Vito M Campese, Larry B Goldstein, Michael G Hennerici

Stroke· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction of major vascular events after stroke: the stroke prevention by aggressive reduction in cholesterol levels trial.
Bruce Ovbiagele, Larry B Goldstein, Pierre Amarenco, Michael Messig, Henrik Sillesen, Alfred Callahan

J Stroke Cerebrovasc Dis· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Alfred Callahan, Pierre Amarenco, Larry B Goldstein, Henrik Sillesen, Mike Messig

Arch Neurol· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Coronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease: findings from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Pierre Amarenco, Larry B Goldstein, Henrik Sillesen, Oscar Benavente, Richard M Zweifler, Alfred Callahan

Stroke· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Statin treatment and stroke outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Larry B Goldstein, Pierre Amarenco, Justin Zivin, Michael Messig, Irfan Altafullah, Alfred Callahan

Stroke· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relative and cumulative effects of lipid and blood pressure control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.
Pierre Amarenco, Larry B Goldstein, Michael Messig, Blair J O'Neill, Alfred Callahan

Stroke· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Pierre Amarenco, Larry B Goldstein, Alfred Callahan, Henrik Sillesen, Michael G Hennerici

Atherosclerosis· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes.
Pierre Amarenco, Oscar Benavente, Larry B Goldstein, Alfred Callahan, Henrik Sillesen

Stroke· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Henrik Sillesen, Pierre Amarenco, Michael G Hennerici, Alfred Callahan, Larry B Goldstein

Stroke· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study.
Larry B Goldstein, Pierre Amarenco, Marian Lamonte, Steven Gilbert, Michael Messig, Alfred Callahan

Stroke· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Pierre Amarenco, Larry B Goldstein, Michael Szarek, Henrik Sillesen, Amy E Rudolph, Alfred Callahan

Stroke· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-dose atorvastatin after stroke or transient ischemic attack.
Pierre Amarenco, Julien Bogousslavsky, Alfred Callahan, Larry B Goldstein, Michael Hennerici

N Engl J Med· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term therapy to prevent stroke.
Howard S Kirshner, José Biller, Alfred S Callahan

J Am Board Fam Pract· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Statins for secondary stroke prevention in patients without known coronary heart disease: the jury is still out.
Larry B Goldstein, Pierre Amarenco, Julien Bogousslavsky, Alfred S Callahan, Michael G Hennerici

Cerebrovasc Dis· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study.
Peirre Amarenco, Julien Bogousslavsky, Alfred S Callahan, Larry Goldstein, Michael Hennerici

Cerebrovasc Dis· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors influencing outcome and treatment effect in PROACT II.
Lawrence R Wechsler, Robin Roberts, Anthony J Furlan, Randall T Higashida, William Dillon, Alfred S Callahan

Stroke· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis